Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in
the acute treatment of moderate or severe migraine in children and adolescents.
Phase:
Phase 3
Details
Lead Sponsor:
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceuticals, Inc.